Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Degarelix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 291,617Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Accord Healthcare's Degarelix Accord (degarelix) Receives Approval in Europe
    Accord Healthcare's Degarelix Accord (degarelix) Receives Approval in Europe

    08 Nov 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/degarelix-accord-epar-medicine-overview_en.pdf

    EMA
    08 Nov 2023
    Share Share
    UCLA researchers to study prostate cancer drug for Covid-19
    UCLA researchers to study prostate cancer drug for Covid-19

    18 May 2020

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/ucla-degarelix-covid-19-trial/

    CLINICALTRIALSARENA
    18 May 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Firmagon 22201 (Degarelix Acetate 80 mg/vial and 120 mg/vial)Powder for Injection
    FDA Confirms Paragraph IV Patent Challenge of Firmagon 22201 (Degarelix Acetate 80 mg/vial and 120 mg/vial)Powder for Injection

    15 Feb 2020

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-firmagon-22201-degarelix-acetate-80-mgvial-and-120-mgvialpowder-for-injection-1581763881.pdf

    FDA
    15 Feb 2020
    Share Share
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Nov 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Nov 2019
    Share Share
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Oct 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Oct 2019
    Share Share
    Myovant's oral prostate cancer drug matches incumbent in phase 3
    Myovant's oral prostate cancer drug matches incumbent in phase 3

    20 Oct 2019

    // N. P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/myovant-s-oral-prostate-cancer-drug-matches-incumbent-phase-3

    N. P Taylor FIERCE BIOTECH
    20 Oct 2019
    Share Share